GA101 Product Description
1、 Product Introduction:
It is a liposome adjuvant system containing 3D-MPLA and QS-21, which can stimulate the production of cytokines by stromal cells, recruit monocytes and neutrophils, promote the differentiation of monocytes into dendritic cells, improve the antigen-presenting ability of dendritic cells in the injection site and draining lymph nodes, and assist in the vaccine to produce a higher immune response.
2. Mechanism of action:
The GA101 liposomal adjuvant effect is produced by 3D-MPLA/QS-21 synergy and is controlled by macrophages.3D-MPLA and QS-21 act synergistically to induce strong antibody and specific CD4 T cell responses. Early release of IFN-γ from NK and CD8 T cells leads to a CD4 T cell response.GA101 induces early production of IFN-γ, which peaks 6 hours after immunization, whereas 3D-MPLA or QS-21 alone fails to induce IFN-γ significantly.
Ref: Lacaille-Dubois Marie-Aleth,Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.[J] . Phytomedicine, 2019, 60: 152905.
3. Scope of application:
Applicable to recombinant protein vaccines, including cancer vaccines, genetically engineered subunit vaccines, etc., such as the recommended application for recombinant herpes zoster vaccine and recombinant respiratory syncytial virus vaccine.
Several approved products as an example to illustrate the role of GA101 adjuvant:
3.1, Herpes zoster vaccine: GA101 adjuvant can induce efficient generation of specific antibodies, and can be used with recombinant gE protein;
3.2, recombinant respiratory syncytial virus vaccine: GA101 adjuvant can be used with recombinant Pre-F protein to induce the generation of higher intensity of humoral and cellular immunity.
4.Product information:
Product Name: GA101
Product Code: GC07001
Grade: GLP grade, GMP grade
Package specification: 50ml/vial, 100ml/vial (customization available)